Which one of the following statement is true about Dipivefrine?
**Core Concept**
Dipivefrine is a prodrug of epinephrine, which is a potent vasoconstrictor used in the treatment of glaucoma to decrease intraocular pressure. The conversion of dipivefrine to epinephrine occurs in the eye, allowing for localized action with reduced systemic side effects.
**Why the Correct Answer is Right**
Dipivefrine is hydrolyzed by esterases in the cornea and conjunctiva to epinephrine, which then acts to reduce intraocular pressure by increasing uveoscleral outflow and decreasing aqueous humor production. This localized conversion to epinephrine reduces the risk of systemic side effects associated with direct epinephrine administration.
**Why Each Wrong Option is Incorrect**
* **Option A:** This statement is incorrect because dipivefrine is not directly metabolized to norepinephrine; instead, it is converted to epinephrine.
* **Option B:** This statement is incorrect because dipivefrine does not primarily act through beta-2 adrenergic receptors; its primary mechanism is through the conversion to epinephrine, which acts on various receptors.
* **Option D:** This statement is incorrect because dipivefrine is not primarily used in the treatment of hypertension; its primary use is in the treatment of glaucoma.
**Clinical Pearl / High-Yield Fact**
Dipivefrine is a useful option in patients with glaucoma who are sensitive to the systemic side effects of epinephrine, and its use can be particularly beneficial in patients with cardiovascular disease.
**Correct Answer: C. Dipivefrine is a prodrug of epinephrine, which is a potent vasoconstrictor used in the treatment of glaucoma to decrease intraocular pressure.**